Overview

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

Status:
Recruiting

Trial end date:
2021-02-28

Target enrollment:

Participant gender:

Summary

This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).

Phase:

Phase 2

Details

Lead Sponsor:

Baylor Research Institute

Treatments:

Sofosbuvir-velpatasvir drug combination